A Win for Trabectedin in High-Grade Myxoid Liposarcoma?
Neoadjuvant trabectedin (Yondelis) for high-grade myxoid liposarcoma (HG-MLPS) demonstrated noninferiority to the long-time standard of anthracycline-ifosfamide (AI), according to new data from a previously completed trial. Standard therapy was associated with twice as many recurrences as compared with trabectedin, translating into a 40% reduction in the hazard for disease-free survival (DFS) in favor of trabectedin. […]
P53 Antagonist Shows Early Activity in Advanced Liposarcoma
CHICAGO — Almost 90% of patients with metastatic liposarcoma achieved disease control with an investigational drug targeting p53 suppression, according to an early study reported at the American Society of Clinical Oncology (ASCO) annual meeting. The results showed that 24 of 32 patients with de-differentiated liposarcoma and MDM2 amplification had stable disease and four other […]